Cardiovascular Systems, Inc. to Participate in Two November Healthcare Conferences
Get Alerts CSII Hot Sheet
Join SI Premium – FREE
ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the Stifel 2022 Healthcare Conference and will host investor meetings at the Canaccord Genuity MedTech Conference.
Stifel 2022 Healthcare Conference
Wednesday, November 16, 2022
1:15 p.m. ET
Webcast
Canaccord Genuity MedTech Conference
Thursday, November 17, 2022
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. For additional information, please visit www.csi360.com and connect on Twitter @csi360.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005207/en/
Cardiovascular Systems, Inc.
Jack Nielsen
Vice President, Investor Relations & Corporate Communications
(651) 202-4919
[email protected]
Source: Cardiovascular Systems, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boost Run Announces Date of Second Quarter 2026 Financial Results Conference Call
- Celestica raises $3.45B in equity offering at $310 per share
- AIxCrypto Holdings Reports Second Quarter 2026 Results
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Stifel, Twitter, Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share